{
  "url": "https://www.law.cornell.edu/regulations/new-york/9-NYCRR-9800.8",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 9800.8 - Audit and claim review",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 9800.8 - Audit and claim review\n\nState Regulations\n(a) Providers shall be subject to audit by the panel, the executive director, their\nagents or the contractor. With respect to such audits the provider may be\nrequired: (1)\nto reimburse the contractor for\noverpayments discovered by audits; and\n(2)\nto pay restitution for any direct or\nindirect monetary damage to the program resulting from their improperly or\ninappropriately furnishing covered drugs. (b) The panel, the executive director, their\nagents or the contractor may conduct or have conducted audits and claims\nreviews which may be limited to reviews of costs of operation or validity of\nclaims submitted, and adherence to accepted pharmacy practices and established\ncontractor policy and procedures, conduct therapeutic drug monitoring reviews\napplying accepted pharmaceutical practice standards or conduct investigations\nas to the provider's conduct relative to fraud or abuse. (c) The contractor upon prepayment review, or\ntherapeutic drug monitoring review, may deny claims, adjust claims to eliminate\nnoncompensable items or to reflect established rates or fees, pend claims for\nreview, or approve the claim for payment, subject to post-payment audit and\nverification. (1)\n\nFor claims denied as a\nresult of therapeutic drug monitoring reviews, as a condition for payment, the\nprovider must submit information indicating that the pharmacist has either\nreviewed the questioned prescription(s), consulted with the participant or\ninteracted with the prescribing physician. Information submitted must describe\nany actions taken as a result of such review, consultation or interaction to\ndeter or prevent the incorrect or unnecessary consumption of a therapeutic\nagent. (2)\n\nFor claims denied as a\nresult of suspected excessive quantities, providers must submit, as a condition\nfor payment, additional dispensing information, such as the dose prescribed, which justifies the quantities billed. (d) Where the contractor's analysis of claims\nor initial onsite audit findings indicate that a provider has claimed or is\nclaiming for covered drugs which may be inconsistent with regulations governing\nthe program or with established standards for quality, or which are otherwise\ninappropriate, payment of all claims submitted and of all future claims may be\ndelayed or suspended, upon the written approval of the executive director, pending completion of an investigation upon approval of the executive director. A notice of the withholding of payment shall be sent to the provider\ncontemporaneous with withholding of payments. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\nยง\n9800.8\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 49821
}